Although the great majority of patients with chronic phase CML have an excellent prognosis, intolerance to currently available TKI is not uncommon and resistance to TKI therapy due to BCR-ABL mutations occurs frequently (1). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.